Seattle Buys Into Future of Genmab ADC Deal

In a six-year-old collaboration with Genmab, Seattle Genetics has decided to exercise its option to co-develop and co-commercialize tisotumab vedotin, an antibody-drug conjugate for solid tumors, granting both companies a 50:50 share.

Digital illustration of Cancer cell in colour background

Seattle Genetics Inc. has decided to exercise its option to co-develop tisotumab vedotin, an antibody-drug conjugate (ADC) currently in Phase I/II trials for solid tumors, under a six-year-old collaboration with Genmab AS. Both companies will now equally share future costs and profits for the product, giving Seattle rights to commercialize in the US, Canada and Mexico and Genmab the remaining territories.

Under a commercial license and collaboration agreement from Oct. 2011, Genmab was given rights to use Seattle's ADC technology and...

More from Anticancer

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By 

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

More from Therapy Areas

Novartis’s Cosentyx Suffers Rare Phase III Fail

 
• By 

Multi-blockbuster falls short in a giant cell arteritis study.

In Brief: 4DMT Fast-Tracks Long-Acting Wet AMD Therapy Trials, Cuts 25% Of Workforce

 

4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.